The effect of NAFLD (non-alcoholic fatty liver disease) on long-term outcome of chronic hepatitis B in Iranian patients

Arezoo Estakhri, Ali Akbari Sari, Sahar Naz Nedjat, Marym Rohban, Naser Rakhshani, Seyed Mohammad Tavangar, Reza Malekzadeh, Ghodrat Montazeri

Digestive Disease Research Center (DDRC), Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
School of Public Health, Knowledge Utilization Research Center, Tehran University of Medical Sciences, Tehran, Iran.

DOI: 10.4236/ojgas.2012.21004                

Abstract

Background: The influence of Non-Alcoholic Fatty Liver Disease on the outcome of chronic hepatitis B disease, including viral, biochemical and histologic characteristics, in Iranian patients is not yet fully un- derstood. Aim: To evaluate the effect of Non-Alcoholic Fatty Liver Disease (NAFLD) on long-term histology- cal, biochemical and viral outcome of chronic he- pa-tictis B in Iranian patients. Methods: We retro- spec-tively evaluated 94 “e Ag” negative chronic hepatitis B patients (with NAFLD: 44, without NAFLD: 50). Non-Alcoholic Fatty Liver Disease was diagnosed based on liver biopsy according to Kleiner classifica-tion. Liver biopsy was done for all patients. Serologi-cal and biochemical variables were evaluated with repeated measure analysis. Results: Non-Alcoholic Fat- ty Liver Disease (NAFLD) was present in 47% of the patients (44 out of 94 patients). In the NAFLD group, increase in AST, ALT, stage (P = 0.002), grade, and total score of liver biopsy were independently related to non-alcoholic fatty liver disease, while HBV-DNA viral load did not correlate with the presence of a fatty liver. Conclusion: Abnormalities of liver enzymes and liver histopathology are more prevalent in concurrent chronic hepatitis B and Non-Alcoholic Fatty Liver Disease (NAFLD).

Keywords

Non-Alcoholic Fatty Liver Disease; Chronic Hepatitis B; IMPACT; Long-Term Prognosis; Iranian

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Bondini, S. and Kallman, J. (2007) Impact of non-alco- holic fatty liver disease on chronic hepatitis B. Liver International, 27, 607-611. doi:10.1111/j.1478-3231.2007.01482.x
[2]	Ganem, D. and Prince, A.M. (2004) Hepatitis B virus in- fection-natural history and clinical consequences. The New England Journal of Medicine, 350, 1118-1129. doi:10.1056/NEJMra031087
[3]	Tran, T.T. and Martin, P. (2004) Hepatitis B: Epidemiol- ogy and natural history. Clinical Liver Disease, 8, 255- 266. doi:10.1016/j.cld.2004.02.008
[4]	Altiparmak, E. and Koklu, S. (2005) Viral and host causes of fatty liver in chronic hepatitis B. World Journal of Gastroenterology, 11, 3056-3059.
[5]	Stephen, A. and Harrison, M. (2002) Nonal-coholic steatohepatitis: What we know in the new Millennium. The American Journal of Gastroenterology, 97, 2714-2724.
[6]	Tsang, S.W.C. and Ng, W.F. (2006) Predic-tors of fibrosis in Asian patients with non-alcoholic steatohepa-titis. Jour- nal of Gastroenterology and Hepatology, 21, 116-121. doi:10.1111/j.1440-1746.2005.04146.x
[7]	Younossi, Z.M. and Deihl, A.M. (2000) Nonalcoholic fat- ty liver disease: An agenda for clinical research. Hepatol- ogy, 35, 746-752. doi:10.1053/jhep.2002.32483
[8]	Gordon, A. and McLean, C.A. (2005) Hepatic steatosis in chronic hepatitis B and C: Predictors, distribution and ef- fect on fibrosis. Journal of He-patology, 43, 38-44. doi:10.1016/j.jhep.2005.01.031
[9]	Lonardo, A. and Adinolfi, L.E. (2004) Steatosis and he- patitis C virus: Mechanismsm and significance for hepa- tic and extrahepatic disease. Gastroen-terology, 126, 586- 597. doi:10.1053/j.gastro.2003.11.020
[10]	Ong, J.P. and Younossi, Z.M. (2001) Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver, 21, 266-271. doi:10.1034/j.1600-0676.2001.021004266.x
[11]	Adinolfi, L.E. and Gambardella, M. (2001) Steatosis ac- celerates the pro-gression of liver damage of chronic he- patitis C patients and correlated with specific HCV geno- type and visceral obesity. Hepatology, 33, 1358-1364. doi:10.1053/jhep.2001.24432
[12]	Chevaliez, S. and Bouvi-er-Alias, M. (2008) Performance of the cobas ampliprep/cobas taqman real-time PCR as- say for hepatitis B virus DNA quan-tification. Journal of clinical Microbiology, 46, 1716-1723. doi:10.1128/JCM.01248-07
[13]	Kleiner, D.E. and Brunt, E.M. (2005) Design and valida- tion of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41, 1313-1321. doi:10.1002/hep.20701
[14]	Bahramali, G. and Sadeghizadeh, M. (2008) Clinical, vir- ological and phylogenetic features of hepatitis Binfection in Iranian patients. World Journal of Gas-troenterology, 14, 448-453
[15]	Westin, J. and Nordlinder, H. (2002) Steatosis accelerates fibrosis development over time in hepatitis c virus geno- type 3 infected patients. Journal of He-patology, 37, 837- 842. doi:10.1016/S0168-8278(02)00299-4
[16]	Wong, G.L.-H. and Wong, V.W.-S. (2009) Metabolic syn- drome increases the risk of liver cirrhosis in chronic he- patitis B. Gut, 58, 111-117. doi:10.1136/gut.2008.157735
[17]	Powell, E.E. and Jonsson, J.R. (2005) Steatosis: Co-factor in other liver diseases. Hepa-tology, 42, 5-13. doi:10.1002/hep.20750
[18]	Thomopoulos, K.C. and Arvaniti, V. (2006) Prevalence of liver steatosis in patients with chronic hepatitis B. Euro- pean Journal of Gastroenterology & Hepa-tology, 18, 233- 237. doi:10.1097/00042737-200603000-00002
[19]	Altlparmak, E. and Koklu, S. (2005) Viral and host causes of fatty liver in chronic hepatitis B. World Journal of Gastroenterology, 11, 3056-3059.